CAMELLIA-TIMI 61 was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.
MAIN RESULTS:
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

N Engl J Med. 2018 Sep 20;379(12):1107-1117.
PRESENTATIONS
Primary Results (Bohula, ESC 2018)
Metabolic Slides (Scirica, EASD 2018)
Renal Outcomes (Bohula, AHA 2018)
Predictive value of echocardiographic markers of diastolic dysfunction for heart failure in overweight and obese patients in CAMELLIA-TIMI 61 (Gong, AHA 2021)
Assessment of Atherothrombotic Risk in Patients with Type 2 Diabetes Mellitus (Berg, ACC 2022)
NT-proBNP, Body Mass Index, and Heart Failure Risk in CAMELLIA-TIMI 61 (Patel, ACC 2023)
Risk Of Kidney Disease Progression And Efficacy Of SGLT2 Inhibition In Patients With Type 2 Diabetes Mellitus (Moura, ACC 2023)
OTHER PUBLICATIONS